ClinicalTrials.gg
CompletedNCT05674019NEMO-BipolarUpdated Nov 20, 2026

MOrphometric MRI Analysis of Cortical Sulci: Development of NEurodevelopmental Biomarkers of Bipolar Disorder.

An interventional study of MRI exam in Bipolar Disorder, sponsored by Assistance Publique Hopitaux De Marseille. Completed at 1 site in France. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by Assistance Publique Hopitaux De Marseille · Not applicable, Interventional, and Other

How we know

Updated Nov 20, 2026Now CompletedFirst site in France+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Non-randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 104 studies in Bipolar Disorder with a site in France — 34 open to participants now, 38 under way, 1 of them phase 3. Bipolar Disorder · France.

Enrollment
46th of 79
120 · median 170
Started
2023
with 6 others
No phase
56 of 104
22 open now
Registered
80th of 104
by date
Lead sponsor
5 of 104
Assistance Publique Hopitaux De Marseille

Among the 104 studies in Bipolar Disorder with a site in France, this one is the 46th largest by enrollment of the 79 interventional ones that give a count, is one of 7 that started in 2023, is one of 56 with no phase, and was the 80th registered.

Bipolar Disorder

1,687 studies on the registry are indexed under Bipolar Disorder; 268 are open to participants now.

Browse Bipolar Disorder studies →

Open to participants now

34 of the 104 studies in Bipolar Disorder with a site in France are open now. Recruiting first, the newest first:

29 more — sign in →

All 34 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 207 Bipolar Disorder studies recruiting now, 60 (29%) set no upper age limit and 134 (65%) stop at 75 or younger; 38 take children under 18; 51 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 104 studies in Bipolar Disorder with a site in France, or all of them as a file.
02

Study summary

Given the phenotypic heterogeneity of bipolar disorder, it seems essential to propose new methodologies to improve the stratification of this pathology in order to describe more homogeneous groups of patients. In this perspective, the neurodevelopmental hypothesis of bipolar disorder seems promising. Brain sulcation is an indirect marker of neurodevelopmental processes. The objective of the study is to highlight sulcal variations between a group of bipolar patients with a neurodevelopmental phenotype (ND) and a group of bipolar subjects without a ND phenotype. A sulcation marker (GPR56) will also be measured from patient blood samples. In order to carry out this project 120 participants will be included for a period of 12 months.

03

Conditions studied

  • Bipolar Disorder

Browse trials for

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

For the "neurodevelopmental" group :

The volunteer has at least 2 of the 12 neurodevelopmental criteria

For the "non-neurodevelopmental" group The volunteer does not present any of the 12 neurodevelopmental criteria

List of the 12 neurodevelopmental criteria :

  1. The volunteer had at birth a paternal age ≥ 40 years
  2. The volunteer had at birth a maternal age ≥ 35 years
  3. The volunteer was born by cesarean section
  4. The volunteer had a history of perinatal infection
  5. The volunteer has a history of generalized anxiety disorder that began before the age of 16 (≤ 15 years)
  6. The volunteer has a history of an eating disorder that began before the age of 16 (≤ 15 years)
  7. The volunteer has a history of a substance use disorder (excluding tobacco) as described in the prior to age 16 (≤ 15 years)
  8. The volunteer has a learning disability or "dys" disorder as defined in the DSM-5 or number of repeats > 2
  9. The volunteer has a history of trauma assessed as severe by the CTQ self-assessment questionnaire
  10. The volunteer has symptoms suggestive of Attention Deficit Hyperactivity Disorder (WURS score > 46)
  11. The volunteer has a history of psychotic features during episodes.
  12. The volunteer has an early age of onset of bipolar disorder at an age below 18 years.

Exclusion criteria

Exclusion Criteria:

  • Serious symptomatic or unstable physiological or medical condition (including pregnancy)
  • History of stable or non-stable psychiatric illness, schizophrenia or any other condition that may interfere with bipolar disorder
  • History of comorbid autism spectrum disorder
  • History of severe head injury (GCS\<8 at time of injury)
  • Neurological disorder affecting central nervous system function
  • Moderate to severe substance use disorder (>=4/11 as defined in the ) with the exception of tobacco use disorder
  • Under court protection or guardianship
  • Unable to give the volunteer informed information, or the volunteer refuses to sign the consent form
  • Insufficient command of the French language to complete the assessments
  • Has a to MRI
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
120 participants (actual)

Study arms

  • Experimental
    Neurodevelopmental Group

    The volunteer presents at least 2 of 12 neurodevelopmental crieria

    Other: MRI exam

  • Active comparator
    Non-neurodevelopmental Group

    The volunteer does not present any of the 12 neurodevelopmental crieria

    Other: MRI exam

Interventions

  • OtherMRI exam

    Brain MRI Morphometric exam

06

What researchers measure

Primary outcomes

  1. Diifference in the occurrence of sulcal pits allowing to discriminate between a group of bipolar patients presenting a neurodevelopmental phenotype and a group of bipolar patients not presenting this phenotype.

    Patients are identified in the neurodevelopmental group following a list of 12 criteria (0 criterion = non neurodevelopmental, at leat 2 criteria = neurodevelopmental)

    Time frame: 24 months

Secondary outcomes

  1. The depth and number of sulcal pits to differentiate a group of bipolar patients with a neurodevelopmental phenotype from a group of bipolar patients without this phenotype.

    Patients are identified in the neurodevelopmental group following a list of 12 criteria (0 criterion = non neurodevelopmental, at leat 2 criteria = neurodevelopmental)

    Time frame: 24 months

  2. The demonstration of correlations between different scores used in the clinic that may be related to neurodevelopmental manifestations of bipolar disorder (scales: WURS, minor neurological signs scale) and the number of sulcal-pits.

    Patients are identified in the neurodevelopmental group following a list of 12 criteria (0 criterion = non neurodevelopmental, at leat 2 criteria = neurodevelopmental)

    Time frame: 24 months

  3. The blood level of GRP56 messenger RNA measured in whole blood by quantitative PCR to differentiate a group of bipolar patients with a neurodevelopmental phenotype and a group of bipolar patients without this phenotype

    Patients are identified in the neurodevelopmental group following a list of 12 criteria (0 criterion = non neurodevelopmental, at leat 2 criteria = neurodevelopmental)

    Time frame: 24 months

  4. Genetic polymorphisms of GPR56 to differentiate between a group of bipolar patients with a neurodevelopmental phenotype and a group of bipolar patients without this phenotype

    Patients are identified in the neurodevelopmental group following a list of 12 criteria (0 criterion = non neurodevelopmental, at leat 2 criteria = neurodevelopmental)

    Time frame: 24 months

  5. Protein quantification of the circulating fraction of GP56 in plasma and serum to differentiate a group of bipolar patients with a neurodevelopmental phenotype from a group of bipolar patients without this phenotype.

    Patients are identified in the neurodevelopmental group following a list of 12 criteria (0 criterion = non neurodevelopmental, at leat 2 criteria = neurodevelopmental)

    Time frame: 24 months

07

Study locations

1 site
  • Hopital de Sainte MArguerite
    Marseille, France
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2023 to primary completion in Jun 2025, 28 months.

Of 361 non-industry interventional studies with no phase under Bipolar Disorder, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 58. This study's 28 months is below that.

Counting every sponsor, half of 363 studies reached it within 37 months; a quarter within 23 and three quarters within 58.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 20, 2026: primary completion Jan 2025 → Jun 2025 and completion Jan 2025 → Jun 2025.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 21, 2022
First posted
Jan 6, 2023
StartActual
Jan 16, 2023
Primary completionActual
Jun 10, 2025was Jan 2025
CompletionActual
Jun 10, 2025was Jan 2025
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Status unknown→Completed
changed Nov 20, 2026
Sites
1 site added — first site in France
Show site
  • Hopital de Sainte MArguerite · Marseille, France
Nov 20, 2026
Start date
Jan 15, 2023→Jan 16, 2023 (actual)
Nov 20, 2026
Primary completion
Jan 14, 2025→Jun 10, 2025 (actual)
Nov 20, 2026
Study completion
Jan 14, 2025→Jun 10, 2025 (actual)
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    Status unknown→Completed
    1 site added — first site in France
    Show site
    • Hopital de Sainte MArguerite · Marseille, France
    Start date Jan 15, 2023→Jan 16, 2023 (now actual)
    Primary completion Jan 14, 2025→Jun 10, 2025 (now actual)
    Study completion Jan 14, 2025→Jun 10, 2025 (now actual)
    + 3 other changes: verification date, description and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05674019
Responsible party
Sponsor
First posted
Jan 6, 2023
Start date
Jan 16, 2023
Primary completion
Jun 10, 2025
Completion
Jun 10, 2025
Last update
Nov 20, 2026

Study contacts

François CREMIEUX
study director · AP-HM

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion